{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.ai-analytics.org/api/v1/entity/SRPT/timeline","_source":{"data_provider":"AI Analytics","data_provider_url":"https://api.ai-analytics.org","license":"https://api.ai-analytics.org/license","usage_info":"https://api.ai-analytics.org/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-09-23T01:26:28.914Z","methodology_url":"https://api.ai-analytics.org/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":9582,"canonical_name":"Sarepta Therapeutics, Inc.","cik":"0000873303","uei":null,"lei":null,"duns":null,"ticker":"SRPT"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","open.payments","dol.form5500","hud.housing","irs.bmf"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":12,"clinical":2,"open":1},"count":15,"timeline":[{"ts":"2026-06-05","kind":"sec.filing","form_type":"4","title":"4 — Wigzell Hans Lennart Rudolf — 2026-06-05","url_slug":"/sec/cik-0001492766/4/0001193125-26-260259","accession_number":"0001193125-26-260259","importance":30},{"ts":"2026-06-04","kind":"sec.filing","form_type":"8-K","title":"8-K — Sarepta Therapeutics, Inc. — 2026-06-04","url_slug":"/sec/cik-0000873303/8-k/0001193125-26-257501","accession_number":"0001193125-26-257501","importance":35},{"ts":"2026-06-04","kind":"sec.filing","form_type":"S-8","title":"S-8 — Sarepta Therapeutics, Inc. — 2026-06-04","url_slug":"/sec/cik-0000873303/s-8/0001193125-26-257643","accession_number":"0001193125-26-257643","importance":30},{"ts":"2026-06-04","kind":"sec.insider.a","reporter":"BEHRENS M KATHLEEN","title":null,"shares":16875,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-04","kind":"sec.insider.a","reporter":"Connelly Deirdre P","title":null,"shares":16875,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-04","kind":"sec.insider.a","reporter":"Wigzell Hans Lennart Rudolf","title":null,"shares":16875,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-04","kind":"sec.insider.a","reporter":"Barry Richard","title":null,"shares":16875,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-04","kind":"sec.insider.a","reporter":"Nicaise Claude","title":null,"shares":16875,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-04","kind":"sec.insider.a","reporter":"Boor Kathryn Jean","title":null,"shares":16875,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-04","kind":"sec.insider.a","reporter":"Mayo Stephen","title":null,"shares":16875,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-06-04","kind":"sec.insider.a","reporter":"Chambers Michael Andrew","title":null,"shares":16875,"price_per_share":null,"usd_value":0,"security_title":"Common Stock","importance":15},{"ts":"2026-05-13","kind":"sec.filing","form_type":"13F-HR","title":"13F-HR — Sarepta Therapeutics, Inc. — 2026-05-13","url_slug":"/sec/cik-0000873303/13f-hr/0001193125-26-221713","accession_number":"0001193125-26-221713","importance":30},{"ts":"2026-05-04","kind":"clinical.trial","reporter":"Sarepta Therapeutics, Inc.","title":"An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in Participants With Duchenne Muscular Dystrophy","security_title":null,"status":"ENROLLING_BY_INVITATION","accession_number":"NCT06270719","excerpt":"[\"Duchenne Muscular Dystrophy\"]","importance":25},{"ts":"2026-04-06","kind":"clinical.trial","reporter":"Sarepta Therapeutics, Inc.","title":"A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT04626674","excerpt":"[\"Muscular Dystrophy, Duchenne\"]","importance":30},{"ts":"2024-12-31","kind":"open.payments","reporter":"Sarepta Therapeutics, Inc.","title":"$1795055.0 to 328 physicians (2024–2024)","security_title":"manufacturer","excerpt":"Elevidys","accession_number":"2024","usd_value":1795055,"importance":70}]}